本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
THE WORLD'S MOST PRESTIGIOUS OSTEOARTHRITIS SOCIETY (OARSI) HELD FOR THE FIRST TIME IN KOREA LONG-TERM SAFETY DATA FROM OVER 1 5 YEARS SUPPORT THE SAFETY PROFILE OF TG-C, WITH PRELIMINARY SIGNS OF POTENTIAL EFFICACY BENEFITS ROCKVILLE, Md., April 28, 2025 /PRNewswire/ -- Kolon TissueGene participated in the 2025 Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis, which took place in Songdo, South Korea, from April 24-27, 2025. This year marked the first time the globally prestigious osteoarthritis society hosted its annual congress in Korea. During the event, Kolon TissueGene presented new long-term data supporting the safety and efficacy of its investigational therapy, TG-C — the world's first cell and gene therapy for osteoarthritis — while highlighting its potential for U.S. FDA approval. On April 25, Kolon TissueGene delivered a presentation titled "TG-C, the First Potential DMOAD*1 Therapy: Intra-Articular Cell-Based Gene Therapy with Long-Term Safety and Insight into Delaying Total Knee Arthroplasty (TKA)". The presentation focused on TG-C's long-term safety profile and its potential to delay total knee arthroplasty (TKA), using long-term follow-up data (US LTS) as a basis. The study included data from 33 subjects who participated in the U.S. Phase 2 trial and 110 subjects from the Phase 3 trial who completed two years of follow-up. The ongoing Phase 3 trial data were analyzed in a blinded manner, including both TG-C and placebo arms, allowing for an objective evaluation of the long-term safety and treatment effects. Safety Results: No treatment-related tumor cases were reported in TG-C enrolled subjects during nearly 15 years of long-term clinical observation in the United States. Moreover, age-specific cancer incidence among TG-C subjects consistently showed lower rates compared to the general U.S. population, based on SEER (Surveillance, Epidemiology, and End Results) data from the U.S. National Cancer Institute — a compelling indicator of TG-C's safety. ▶ Age-Specific Cancer Incidence: TG-C U.S. Long-Term Follow-Up (US LTS) vs. U.S. Average (SEER) Efficacy Results: Kolon TissueGene also presented data comparing the rate and timing of knee replacement surgery among TG-C–treated subjects versus the broader osteoarthritis population*2 in the U.S. According to the Osteoarthritis Initiative (OAI), which includes 11 years of longitudinal data sponsored by the U.S. National Institutes of Health (NIH), 15.5% of 595 patients meeting TG-C–eligible criteria underwent TKA at a median of 5.1 years after osteoarthritis onset. In contrast, only 7.0% of TG-C–treated subjects underwent TKA, with the median time to surgery extended to 5.7 years. These findings suggest that TG-C may either replace or significantly delay the need for surgical intervention — a hallmark of a disease-modifying osteoarthritis drug (DMOAD). The data supports TG-C's potential to slow structural progression of osteoarthritis and offers a meaningful therapeutic alternative. Executive Commentary: Dr. Moon Jong Noh, Co-CEO of Kolon TissueGene, stated, "We are honored to share meaningful TG-C data at the first-ever OARSI congress held in Korea. This opportunity reinforces our optimism for FDA approval and recognition of TG-C as the world's first DMOAD therapy." Co-CEO Seng Ho Jeon, who joined the company in March, added, "The scientific data presented strongly supports the safety and efficacy of TG-C. We are pursuing parallel strategies for both regulatory approval and commercialization to establish TG-C as a global blockbuster treatment." About OARSI: Headquartered in New Jersey, USA, the Osteoarthritis Research Society International (OARSI) is the world's leading organization for scientists and healthcare professionals working in the field of osteoarthritis prevention and treatment. Each year, the society holds its global congress in major cities worldwide, drawing over 1,500 experts from more than 50 countries, including clinical researchers, orthopedic specialists, radiologists, and physical therapists. About TG-C: TG-C is the world's first cell and gene therapy developed for knee osteoarthritis and is classified as a first-in-class investigational drug. It is currently undergoing follow-up in a U.S. Phase 3 trial following completion of dosing. As of 2024, the osteoarthritis market in the seven major countries (U.S., France, Germany, Italy, Spain, U.K., and Japan) is estimated at KRW 3.8 trillion, with a projected compound annual growth rate of 5.3%, reaching KRW 5.5 trillion by 2031. The global market is expected to exceed KRW 12 trillion. Currently dominated by low-cost analgesics, the introduction of effective disease-modifying therapies like TG-C could significantly expand market potential. (Source: GlobalData, Osteoarthritis: Epidemiology Forecast to 2031, June 17, 2022) (*1) Disease-Modifying Osteoarthritis Drug(*2) Data from the Osteoarthritis Initiative (OAI), a large-scale, public, long-term follow-up study sponsored by the U.S. National Institutes of Health (NIH). ▶ Dr. David Hunter presenting on TG-C at the OARSI World Congress
YANTAI, China, April 28, 2025 /PRNewswire/ -- A landmark seawater desalination plant, designed and built by SUEZ for Wanhua Chemical Group—one of the world's top 20 chemical companies—has officially begun operations at Wanhua Chemical's Penglai Industrial Park in Yantai, Shandong. Designed with a total capacity of 300,000 m3 per day to be delivered in three phases, this is the largest industrial membrane-based seawater desalination project planned in China to date. Officials from local government, and representatives from key partners—including Wanhua Chemical Group, China Railway Shanghai Engineering Group Co., Ltd., Beijing Shougang International Engineering Technology Co., Ltd., and SUEZ, gathered to mark this significant milestone in Sino-French cooperation in sustainable water solutions. LIAO Zengtai, Chairman of Wanhua Chemical Group, said: "The completion of the Penglai seawater desalination project represents not only a firm step forward for Wanhua's journey toward green and low-carbon industrial development, but also a significant milestone in the innovation and application of seawater desalination technology in China. Through our partnership with SUEZ, the project has achieved a world-leading standard by employing the advanced technology and the optimal process, thereby establishing a global benchmark for energy efficiency in the seawater desalination industry. As a leader in the chemical new materials industry, Wanhua will continue to partner with SUEZ to drive industry transformation and contribute to the global seawater desalination sector." Pierre PAULIAC, Co-CEO of SUEZ and Chief Operating Officer Water, said: "With nearly 60 years of experience in designing, building, and operating more than 260 desalination plants worldwide, SUEZ delivers tailored, high-performance solutions for municipal and industrial clients. The Penglai facility, constructed to the highest industrial standards, is a landmark project between SUEZ and Wanhua Chemical Group, building on our successful partnership since 2017. The commissioning of the first phase today sets a benchmark for seawater desalination in coastal regions across China. It stands as a powerful example of what is possible when innovation, ambition, and partnership come together, to address the urgent need for fresh water in coastal areas." WANG Jianying, Chairman of China Railway Shanghai Engineering Group Co., Ltd., said: "This marks the largest industrial membrane-based desalination project currently planned in China. With the shared mission to build it into a 'lighthouse' project, China Railway Shanghai Engineering Group has leveraged extensive resources, applied scientific planning, and maintained rigorous safety and quality management throughout the process. With the concerted efforts of the consortium partners, we achieved the high-quality delivery of the entire facility within 14 months, demonstrating our team's unwavering commitment, resilience, and pursuit of the highest standards." WU Liyun, Chairman of Beijing Shougang International Engineering Technology Co., Ltd., said: "With nearly 800 projects for over 200 clients worldwide, this high-quality project exemplifies Shougang International Engineering's commitment to technology-driven innovation, utilising BIM technology to integrate the entire lifecycle of the desalination plant. Today, together with our partners, Wanhua Chemical Group, SUEZ, and China Railway Shanghai Engineering Group—all are leading companies in their respective fields—we celebrate this fruitful international cooperation in sustainable water solutions. We look forward to contributing further to the sustainable development of global water resources." Setting a new benchmark for China's industrial seawater desalination plant As a global leader in membrane-based seawater desalination engineering, SUEZ brings international expertise and innovation to this plant. The Group deploys advanced reverse osmosis membrane technology to convert seawater into freshwater, supplying it as the primary industrial water source for Wanhua Chemical's Penglai Industrial Park. The facility employs low-carbon, energy-efficient, and environmentally responsible processes, achieving over 15% cost savings compared to conventional dual-membrane technologies[1]. With the full commissioning of first phase, it will produce 100,000 m³ of desalinated water daily, resulting in annual savings of over 36 million m³ of freshwater. Additionally, the facility features a highly advanced automation system, making it China's first fully automated desalination plant. Meeting industrial water needs and preserving resources As part of its national water security strategy, China is broadening the large-scale application of seawater desalination. Shandong Province, for instance, faces acute water scarcity, with per capita water resources measured at less than one sixth of the national average. Leveraging its geographical advantages, Shandong has prioritised seawater desalination as a strategic, fast-developing industry. This Penglai facility is a flagship initiative under China's and Shandong Province's seawater desalination strategies. Its signing during French President Emmanuel Macron's state visit to China in April 2023—witnessed by senior officials from both countries—marks an important milestone in Sino-French cooperation on sustainable water solutions. By enhancing regional water resilience, the project helps ease local freshwater shortages while conserving scarce resources. It also sets a replicable model for water security in coastal areas and supports the climate change adaptation in the industrial sector. SUEZ and its partners mark the commissioning of the seawater desalination plant at Wanhua Chemical’s Penglai Industrial Park. [1] The "dual-membrane technologies" integrates UF and RO technologies for desalination. About SUEZ: Faced with growing environmental challenges, SUEZ has been delivering essential services that protect and improve our quality of life for more than 160 years. SUEZ provides its customers with innovative and resilient solutions for water and waste services. With 40 000 employees across 40 countries, the Group works with customers to create value over the full lifecycle of their assets and services, and to drive their low carbon transition. In 2024, SUEZ provided drinking water for 68 million people worldwide and sanitation services for 44 million people. The Group generated 8 TWh of energy from waste and wastewater. In 2024, SUEZ has generated revenues of 9.2 billion euros. For more information: www.suez.com/ Twitter @suez In Asia, SUEZ's journey began some 70 years ago, first in Southeast Asia before expanding to China 50 years ago. With 6,500+ employees across Asia, SUEZ has built over 600 water and wastewater treatment plants. Together with our local partners, we also provide water and waste recycling and recovery services to 25+ million people and 22 industrial parks across the region. SUEZ is recognized as one of the most influential companies in China and a service benchmark for leading Asia's environmental industry. Today, SUEZ works with municipal and industrial customers in more than 30 major cities and regions across China, manages China's first PPP water contract in Macao, operates one of Asia's largest hazardous waste incineration facilities in Shanghai, and has invested over RMB 6 billion in Chongqing.
SINGAPORE, April 21, 2025 /PRNewswire/ -- Mega Matrix Inc. (NYSE American: MPU) announced that Yuder Pte. Ltd. ("Yuder"), a indirectly wholly owned subsidiary of it, has signed a Memorandum of Understanding (MOU) with Interactive Films LLC ("Interactive Films"), a subsidiary of Snail, Inc. (Nasdaq: SNAL) ("Snail Games"), a leading global independent developer and publisher of interactive digital entertainment. Under this MOU, both parties will leverage their respective strengths to establish a comprehensive collaboration framework for the joint development, production, and global distribution of short dramas, further enhancing their presence in the entertainment industry. Mr. Yucheng Hu, CEO of MPU, also commented, "This partnership marks an important step for MPU as we expand our content portfolio and strengthen our presence in the global short-drama industry. Short dramas are seeing increasing popularity, with audience demand for binge-worthy, serialized content on the rise. With Snail Games' growing integration in artificial intelligence (AI) in its development pipeline and its track record of immersive, story-driven digital entertainment, combined with MPU's established production and distribution capabilities, we believe this collaboration has the potential to deliver engaging content that resonates with global audiences". Snail Games (NasdaqCM: SNAL) is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs and mobile devices. Mr. Hai Shi, Chairman and Co-CEO of Snail Games, commented, "Today's announcement marks the official launch of our short-drama business. According to WiseGuyReports, the global mini-program short drama market is projected to expand from USD 5.66 billion in 2024 to USD 25.68 billion by 2032, reflecting a strong CAGR of 20.81%. North America, a key market for short-form content, is expected to generate USD 1.89 billion in revenue in 2024, driven by the rapid adoption of streaming services and the growing presence of major industry players. This upward trend underscores the increasing consumer demand for short-form video content, presenting a timely opportunity for our collaboration with MPU to deliver engaging short dramas to audiences worldwide." Under the non-binding, non-exclusive MOU, through Yuder and Interactive Film, MPU and Snail Games will explore collaboration on the creative direction and script development of short dramas, production and global distribution of short-form dramas. Leveraging its experienced in-house team and extensive expertise in short-drama production, MPU will oversee outsourced production and post-production to ensure high-quality content. Additionally, Snail Games' expertise in AI and interactive technologies, honed through game development, may be integrated into personalized recommendations and interactive storytelling, delivering a next-generation immersive viewing experience for audiences. Although the MOU is non-binding, it reflects the parties' shared intention to explore co-development of a pipeline of short dramas. By utilizing their well-established international distribution channels in gaming and micro-drama markets, these productions will quickly reach audiences across North America, Southeast Asia, and other global regions, further amplifying both companies' influence in the global entertainment sector.Under the terms of the MOU, the parties intend to enter into definitive agreement within 45 days. This strategic partnership marks a significant step of the short drama business for Snail Games and a significant milestone in MPU's expansion within the entertainment industry. By aligning with Snail Games, MPU can integrate both parties' strengths in content creation and technology while leveraging MPU' global distribution resources to accelerate the worldwide rollout of short dramas. This collaboration is expected to accelerate Snail Games' entry of the short drama market while providing audiences with a diverse selection of high-quality short dramas. About Mega Matrix Inc.: Mega Matrix Inc. (NYSE American: MPU) is a holding company and operates FlexTV, a short-video streaming platform and producer of short dramas, through its subsidiary, Yuder Pte, Ltd. Mega Matrix Inc. is a Cayman Island corporation headquartered in Singapore. For more information, please contact info@megamatrix.io or visit: http://www.megamatrix.io. About Snail Games: Snail Games (NasdaqCM: SNAL), is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs and mobile devices. For more information, please visit: https://snail.com/ Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements that are purely historical are forward looking statements. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose," and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees for future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, are: that Yuder and Interactive Films will enter into definitive agreements; that the mini-program short drama market will continue to expand as anticipated; the ability to manage growth; ability to identify and integrate future acquisitions; ability to grow and expand our FlexTV business; ability to obtain additional financing in the future to fund capital expenditures; fluctuations in general economic and business conditions; costs or other factors adversely affecting the Company's profitability; litigation involving patents, intellectual property, and other matters; potential changes in the legislative and regulatory environment; a pandemic or epidemic; the possibility that the Company may not succeed in developing its new lines of businesses due to, among other things, changes in the business environment, competition, changes in regulation, or other economic and policy factors; and the possibility that the Company's new lines of business may be adversely affected by other economic, business, and/or competitive factors. The forward-looking statements in this press release and the Company's future results of operations are subject to additional risks and uncertainties set forth under the heading "Risk Factors" in documents filed by the Company with the Securities and Exchange Commission ("SEC"), including the Company's latest annual report on Form 20-F, filed with the SEC on March 28, 2025, and are based on information available to the Company on the date hereof. In addition, such risks and uncertainties include the Company's inability to predict or control bankruptcy proceedings and the uncertainties surrounding the ability to generate cash proceeds through the sale or other monetization of the Company's assets. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. Disclosure Channels We announce material information about the Company and its services and for complying with our disclosure obligation under Regulation FD via the following social media channels: X (f/k/a Twitter): twitter.com/MegaMatrixMPU Facebook: facebook.com/megamatrixmpu facebook.com/flextvus LinkedIn: linkedin.com/company/megamatrixmpu TikTok: tiktok.com/@flextv_english YouTube: youtube.com/@FlexTV_English The Company will also use its landing page on its corporate website (www.megamatrix.io) to host social media disclosures and/or links to/from such disclosures. The information we post through these social media channels may be deemed material. Accordingly, investors should monitor these social media channels in addition to following our website, press releases, SEC filings and public conference calls and webcasts. The social media channels that we intend to use as a means of disclosing the information described above may be updated from time to time as listed on our website. For inquiries, please contact: Info@megamatrix.io
SHANGHAI, April 16, 2025 /PRNewswire/ -- Henlius (2696.HK) held its 2025 Global R&D Day under the theme of "Collaborate to Create". Senior executives from Henlius gathered with leading experts, scholars, and heads of innovation from across the industry to engage in in-depth discussions on the latest advances in R&D, future strategic planning, and the deployment of cutting-edge technologies and therapies. The event drew hundreds of guests from academia, industry, and the investment community, making it a grand gathering of shared insight and collaboration. Jason Zhu, Executive Director and CEO of Henlius, stated: "At Henlius, we remain steadfast in our patient-centric philosophy and continue to strengthen our differentiated competitive edge through innovation-driven R&D. We are advancing the development of several key innovative assets, including HANSIZHUANG (serplulimab, anti-PD-1 mAb), HLX22 (anti-HER2 mAb), and HLX43 (PD-L1 ADC), with the potential to reshape the treatment landscape for lung and gastrointestinal cancers. Beyond that, we are actively exploring frontier technologies such as targeted therapies, immunotherapies, and glyco-editing, as we build a diversified innovation platform. In terms of global expansion, Henlius is strategically focused on major markets such as the U.S., EU, and Japan. Through full value chain integration and deepening international partnerships, we are making a strategic leap from exporting products to building a global value chain. Looking ahead, Henlius will continue to focus on antibody drug innovation, accelerate breakthroughs in targeted and immune therapies, and drive the global advancement of China's innovative biologics. Our goal is to deliver high-quality, affordable biologics to patients around the world while forging a sustainable, globally integrated value core." Jijun Yuan, CSO of Henlius, elaborated on the company's differentiated innovation strategy: "Henlius' R&D strength is reflected not only in our innovative pipeline but also in the continuous expansion of our platform capabilities. We focus on key therapeutic areas such as oncology and autoimmune diseases, extending our innovation reach to diverse modalities—including protein-based therapies, small molecules, and ADCs—to maximize synergistic potential across pipeline assets. Our three flagship technology platforms—the Hinova TCE (tri-specific T-cell engager) platform, the independently developed ADC platform Hanjugator™, and the AI-driven drug discovery platform HAI Club—have formed a collaborative R&D matrix. Leveraging these platforms and AI-driven approaches, we are accelerating the development of differentiated molecules, such as TCEs for solid tumors, to rapidly deliver more potential blockbuster therapies." In Henlius' innovative pipeline, late-stage clinical assets such as HLX22 and HLX43 have emerged as breakthrough candidates, underscoring the company's potential to drive future growth. Lixin Feng, Strategic Products Deputy GM of Henlius, shared that, "HLX43 is a precisely designed ADC targeting the pan-tumor antigen PD-L1. Its core framework incorporates the company's proprietary novel anti-PD-L1 mAb, combined with MediLink Therapeutics' innovative linker-toxin payload featuring a dual-release mechanism (intracellular and extracellular). As the world's second and China's first PD-L1 ADC to enter clinical development, HLX43 has demonstrated early potential as an innovative PIP (pipeline in a pill).Preclinical studies have shown favorable druggability and safety profiles with significant tumor-killing activity. Meanwhile, clinical studies of HLX43 as both monotherapy and in combination with HANSIZHUANG are accelerating across multiple solid tumors, with the potential to deliver superior treatment options for patients." At the event, Professor Lin Shen, the leading principal investigator of the MRCT Phase 3 trial for HLX22, remarked: "Henlius' HLX22 is a highly promising HER2-targeted therapy distinguished by both its mechanism of action and clinical performance. Its differentiated molecular design enables simultaneous binding to HER2 alongside trastuzumab, synergistically blocking all HER2 dimer formation and disrupting HER2-mediated signaling pathways. Moreover, HLX22's clinical development strategy is both pioneering and ambitious—it targets gastrointestinal cancers, a field with urgent unmet needs and high heterogeneity, where the drug has demonstrated exceptional antitumor efficacy. This positions HLX22 to potentially redefine first-line treatment for HER2-positive gastric cancer. HLX22 has demonstrated clinical development potential as a pan-tumor therapeutic for all HER2-positive cancers. We look forward to HLX22 benefiting more patients worldwide." Henlius is strategically advancing key innovations in biopharma by harnessing AI to sharpen its cutting-edge capabilities. Simon Hsu, CTO and SVP of Henlius, highlighted breakthroughs in AI-driven drug development, with a focus on next-generation hyaluronidase Henozye™, "Utilizing AI modeling, Henozye™ achieved significantly faster development cycles versus conventional methods while demonstrating superior enzyme activity and stability. Its exceptional performance across buffer systems and co-formulations provides critical support for subcutaneous delivery—overcoming injection volume limits to enable high-dose drug development," He emphasized that this hyaluronidase platform will transform the subcutaneous delivery market. "Through collaborative partnerships, we're accelerating subcutaneous formulations for both novel drugs and biosimilars, extending product lifecycles sustainably." While deepening its presence in Europe and the U.S. and expanding into emerging markets in Southeast Asia, Henlius is advancing its Globalization 2.0 strategy with a focused breakthrough in the Japanese market. Leveraging the advantages of geographic proximity and ethnic similarity for clinical development, along with Japan's status as the world's third-largest pharmaceutical market—supported by an aging population and a robust universal healthcare system—Henlius positions Japan as a strategic stronghold for the global rollout of its innovative biologics. Jin Li, Vice President of Henlius Regulatory Affairs, stated that "We are advancing our Internationalization 2.0 Strategy with Japan as a key market, leveraging the differentiated advantages of our core pipeline assets HLX22 (anti-HER2 mAb) and serplulimab (HLX10, anti-PD-1 mAb) in gastric cancer and lung cancer. We have initiated clinical trials in Japan to establish foundational support for indication development. Japan represents a strategic priority as a global pharmaceutical hub, offering unique opportunities through its aging population dynamics and innovative drug policy environment. We are systematically building local operational capabilities while strengthening our market position through innovative biologics. By integrating global clinical resources with localized strategies, we are creating an end-to-end value chain from clinical development to commercialization. As a Chinese biopharma innovator, we are reshaping the landscape in global markets through this approach." Henlius is committed to building a global innovation network and fostering an international collaborative ecosystem, setting a benchmark for partnerships spanning product development, market access, and localized operations. During the panel discussion moderated by Henlius SVP and Chief Business Development Officer, Ping Cao, 2022 Nobel Laureate and Palleon Co-founder Professor Carolyn Bertozzi, Palleon CEO James Broderick, MediLink CMO Steve Chin, KGbio CEO Sie Djohan and Sermonix Founder and CEO David Portman joined the discussion under the theme "Partnering for Success - Building a Global Biopharma Ecosystem." Professor Carolyn Bertozzi highlighted the critical role of sialoglycans in disease treatment, particularly their mechanism in tumor immune evasion and autoimmune diseases, as well as their vast potential as a cutting-edge global technology for novel drug development. Palleon is actively advancing its proprietary Enzyme-Antibody Glycan Ligand Editing (EAGLE) platform and has entered into collaborations with Henlius to develop bifunctional antibody-sialidase fusion proteins and human sialidase fusion protein HLX79 (E-602)—leveraging the EAGLE platform to target cancer and autoimmune diseases, respectively. During the follow-up discussion, panelists unanimously recognized Henlius' comprehensive capabilities spanning cutting-edge innovation, clinical development, and manufacturing excellence, while particularly commending the team's efficient collaboration and responsive partnership approach. Industry partners emphasized that their decision to collaborate with Henlius was rooted in strong confidence in the company's fully integrated biopharmaceutical platform that covers the entire value chain from research to commercialization. With established expertise in antibody development and a demonstrated ability to execute rapid yet reliable clinical strategies, Henlius has built a world-class manufacturing quality system meeting international standards, creating a robust foundation for global commercialization. Ping articulated the company's partnership philosophy: "We build on trust as our foundation, drive progress through efficiency, and connect through innovation." This guiding principle continues to shape Henlius' growing global collaborative ecosystem. Moving forward, the company remains committed to deepening complementary technology partnerships and accelerating exploration in frontier therapeutic areas. By leveraging its strong partner network, Henlius aims to enhance worldwide access to innovative therapies and deliver high-quality treatment solutions to patients across the globe. In biopharmaceutical R&D, the translational gap from preclinical research to clinical application remains a persistent challenge across the industry. For Henlius, this very gap represents a critical breakthrough point to truly deliver clinical benefit by staying centered on the patient. At the close of the event, Jijun Yuan moderated a panel discussion on the theme "From Discovery to Delivery: Patient-Centric Innovation in Practice." He was joined by Lei Tang, Head of Translational Medicine Unite China R&D at Sanofi; Li Peng, CSO of Palleon; Feng Ren, Co-CEO and CSO of Insilico; and Guoqiang Hua, Founder and Chairman of Dan1Med. Guests shared insights from the perspectives of multinational pharma, cutting-edge biotech, AI-driven biopharma company and technology platform company. Discussions spanned innovations in tools that enhance precision in clinical trial design, the acceleration of R&D through advanced AI-driven data strategies, and the current challenges faced. Ultimately, all perspectives converged on a shared vision: building a collaborative, barrier-free ecosystem is essential to truly achieving a seamless transition "from discovery to delivery." From biosimilars to first-in-class therapies, and from deepening presence in mainstream markets to expanding into multi-polar global markets, Henlius continues to push the boundaries of the industry with its multiple driving forces such as innovation and globalization. In 2025, Henlius will remain committed to its core theme of "Collaborate to Create", further powering its innovation engine to accelerate the transformation from technological strength to clinical value. The company aims to drive explosive growth across its innovative pipeline while advancing both technological breakthroughs and international collaboration. Looking ahead, Henlius will continue to write a new chapter for China's biopharmaceutical industry on the global stage—bringing Chinese innovation to contribute to the advancement of human health worldwide. About Henlius Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 6 products have been launched in China, 4 have been approved for marketing in overseas markets, and 5 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP. Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company's launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe), the world's first anti-PD-1 mAb for the first-line treatment of SCLC, and HANNAIJIA (neratinib). What's more, Henlius has conducted over 30 clinical studies for 19 products, expanding its presence in major markets as well as emerging markets.
NEW YORK, April 11, 2025 /PRNewswire/ -- Dany Garcia, Chairwoman & CEO of The Garcia Companies, announces the launch of Danimás, an innovative media company and community built for the modern Trailblazer. Designed to inspire individuals who embody the "Athlete of Life™" mindset, Danimás celebrates ambition and the journey, through the triumphs and defeats, for the pursuit of greatness in every facet of life. Backed by original research Garcia personally funded—which revealed that 65% of women feel underrepresented in media—Danimás will be home to dynamic content, first-person narratives, original programming, and cultural storytelling that shifts perspective and breaks boundaries. Danimás is more than just a media platform — it's a movement and a mindset. At its core, it's a digital space that connects individuals who embrace strength as a lifestyle choice, extending beyond the gym and into their personal, professional, and creative pursuits. As a brand, it seeks to serve as a cultural touchpoint, highlighting individuals who are redefining industries — from leading entrepreneurs and athletes to creative visionaries and fashion innovators. "The Trailblazer represents a new archetype — glamorous, bold, and unapologetic. Strength training is the great unlock to harnessing her innate power; She embraces her strength, allowing it to reverberate and leave a lasting impact on herself and others," says Garcia. "Danimás is where these individuals can find a community that fuels their ambitions and inspires their journeys." Garcia, a professional bodybuilder, lifelong athlete, and accomplished entrepreneur who oversees a diversified portfolio of companies that span entertainment, media, fashion, sports, health, wellness, and consumer goods, brings a unique blend of business acumen and physical discipline to this groundbreaking initiative. Over the past decade, Garcia has played a pivotal role in producing culturally significant and commercially successful projects, including HBO's five-time-Emmy-nominated Ballers and blockbuster films such as Sony's globally beloved Jumanji franchise, Disney's Jungle Cruise and upcoming Live Action Moana, Netflix's Red Notice, Amazon's Red One, among others. Garcia has appointed Liz Edmiston as Co-CEO of the Fashion Division at The Garcia Companies, where she will spearhead the development of Danimás. A dynamic and seasoned global retail leader, Edmiston most recently served as CEO of Lane Bryant, where she revitalized and modernized the beloved fashion brand, and as President and CEO of Groupe Dynamite Inc., in Montreal, guiding the company through a digital evolution and shaping its strategic growth trajectory. As Chief Brand Officer of Calvin Klein, she oversaw the Asia Pacific region based in Hong Kong, transforming it from a licensed model to a fully owned and operated retail business with over 2600 stores. She has also held senior executive positions for companies such as Gap, Inc., Ralph Lauren, Tory Burch, and Victoria's Secret. "Liz is a powerhouse — she understands how to build brands that move culture," said Garcia. "Her proven ability to lead with discipline, resonate with consumers, and execute at scale make her the perfect partner to bring Danimás to life." "Danimás is an exciting new concept," said Edmiston. "It's a brand built on strength and intention — where training meets style, and where creativity is expressed through every detail. This isn't just about a new content platform or fashion focused company, it's about building a community of power women who are interested in business, sports, fashion and culture and are intent on getting the most out of life." For the launch, Danimás has partnered with Frosty, a premier global creative agency, and branding specialist Studio Alistair Gibbs to shape the brand's identity and visual narrative, culminating in a striking debut campaign. Shot in London by renowned photographer Amber Pinkerton, the campaign, which showcases the first visual world of Danimás, merges power, training, strength, and glamour in a visually arresting and thought-provoking manner. Danimás Debuts Online Danimás will launch digitally on www.danimas.com with an expansive range of editorial content, visuals and storytelling.The brand will also maintain an active presence on Instagram and LinkedIn starting April 10, 2025, offering exclusive content and updates that reflect its community-first approach. A newsletter will be rolled out later this month to subscribers. The company has partnered with Studio K&J and Sweden Unlimited on the website launch, with In*houseco Inc, managing creative execution across all platforms. The Executive Team Danimás boasts an impressive leadership team that blends diverse expertise from across industries. The team includes: Giuseppe Cielo, former CFO at Khaite – Chief Financial Officer Amy Madigan, former VP, Operations at GSTQ - Chief of Staff Erin Lardy, Chief Content Officer of The Garcia Companies - Interim Chief Editorial Director Lynn Ambrose, former Head of Talent for The RealReal – Human Resources Advisor. Shanna Goldstone and Jason Cauchi of Pari Passu New York, and SAGO, have been retained to conduct consumer research. Ave Advisory has been retained for executive marketing strategy. Karen Harvey Consulting Group is leading executive search and supporting brand development and strategic initiatives. For more information and media inquiries, please contact: Press Inquiries: info@danimas.com Visual from Danimás brand launch, merging power, training, strength, and glamour for the modern Trailblazer. Logo - https://mma.prnasia.com/media2/2661467/Danimas_Logo.jpg?p=medium600Photo - https://mma.prnasia.com/media2/2661466/Danimas_IP_Image.jpg?p=medium600
ILOILO CITY, Philippines, April 7, 2025 /PRNewswire/ -- SUEZ, a global leader in environmental services, and JEMCO, a premier construction company in the Philippines, together with Metro Pacific Water, a key water and wastewater infrastructure investor fully-owned by Metro Pacific Investments Corp. (MPIC), commenced the construction of a seawater reverse osmosis (SWRO) desalination facility in Metro Iloilo— the largest of its kind in the Philippines. Slated to be completed in 24 months, this project will help address the critical shortage of drinking water in the region, supplying sustainable and reliable potable water to local communities. The existing fresh water sources in Metro Iloilo have become severely strained and are no longer capable of meeting the increasing demand of the region. This situation has been exacerbated by seasonal fluctuations in rainfall, disrupting the replenishment of these finite water supplies, revealing the urgent need to identify and develop alternative sources of water to ensure the long-term sustainability of the region. To tackle the region's shortage of potable water, Metro Pacific Water awarded to SUEZ and JEMCO a project to design, build and operate a seawater reverse osmosis desalination facility. The SWRO desalination plant will have an estimated production capacity of 66,500 cubic meters per day, with over 97% of which to be supplied to the residents as drinking water, benefiting approximately 50,000 households. The remaining part will be used for the production of demineralised water to support the operation of the adjacent power plant. As a leader of circular solutions for water and waste services for more than 160 years, SUEZ has 50 years of experience in seawater desalination, with over 260 desalination plants designed and built worldwide. This plant will incorporate SUEZ's flagship technologies, such as the SeaDAF™ Filter which combines the dissolved air flotation technology and dual media gravity filter to treat seawater and remove algae, turbidity, suspended solids, and colloidal particles to reach a quality suitable to feed to the reverse osmosis membranes. Its compact design makes it suitable for installations where space is a premium. A testimony to the strong partnership between SUEZ and JEMCO, this is the second project that the two entities have worked on together, with the first being a key water reclamation facility in Muntinlupa City, Metro Manila. SUEZ has a strong presence in the Philippines with a well-established local engineering platform and a professional team of local talents. The collaboration will leverage SUEZ's expertise and technologies in seawater desalination, and benefit from the strong local experience and construction capabilities of JEMCO. Iloilo City Mayor Jerry Treñas said: "This exceptional initiative seeks to ensure a consistent and reliable supply of potable water for Ilonggos, enhancing their quality of life while bolstering Iloilo's infrastructure and driving economic growth." Christopher Andrew B. Pangilinan, CEO and President of Metro Pacific Water said: "MPW's commitment to providing sustainable water solutions is at the heart of this project. It underscores our dedication to supporting Iloilo's rapid growth and development. This innovative and sustainable desalination facility will provide a long-term solution to the water challenges of Iloilo." Augusto F. Manalo, President & CEO of JEMCO noted: "The large-scale Seawater Reverse Osmosis (SWRO) plant in Metro Iloilo is of vital importance to the region and one which would mark a major milestone to be the largest plant of its kind in the Philippines. We thank the Metro Pacific Water Investment Corporation for this opportunity to be able to deliver this critical infrastructure project. We are proud to be partnering once more with SUEZ, one of the world's leading provider of solutions for sustainable management of resources. It has always been JEMCO's mission to be a major contributor to nation building and we believe that being part of a project such as this further reinforces our drive to be true to our mission." Pierre Pauliac, Co-CEO of SUEZ and Chief Operating Officer Water said: "Given the critical water situation in the region, we are determined to secure a stable and reliable water supply for our customers by leveraging our 50 years of experience and technological know-how in seawater desalination worldwide. This collaboration is a testament to the trust our partners and clients place in us, and a new step in SUEZ's expansion in Southeast Asia." SUEZ and partners commence construction of Philippines’ largest seawater desalination plant in Metro Iloilo. About SUEZ: Faced with growing environmental challenges, SUEZ has been delivering essential services that protect and improve our quality of life for more than 160 years. SUEZ provides its customers with innovative and resilient solutions for water and waste services. With 40,000 employees across 40 countries, the Group works with customers to create value over the full lifecycle of their assets and services, and to drive their low carbon transition. In 2023, SUEZ provided drinking water for 57 million people worldwide and sanitation services for more than 36 million people. The Group generated 7.7 TWh of energy from waste and wastewater. In 2023, SUEZ generated revenues of 8.9 billion euros. For more information: www.suez.com / X @suez / LinkedIn @SUEZ. In Asia, SUEZ's journey began some 70 years ago, first in Southeast Asia before expanding to China 50 years ago. With 6,500+ employees across Asia, SUEZ has built over 600 water and wastewater treatment plants. Together with our local partners, we also provide water and waste recycling and recovery services to 25+ million people and 22 industrial parks across the region. SUEZ is recognized as one of the most influential companies in China and a service benchmark for leading Asia's environmental industry. Today, SUEZ works with municipal and industrial customers in more than 30 major cities and regions across China, manages China's first PPP water contract in Macao, operates one of Asia's largest hazardous waste incineration facilities in Shanghai, and has invested over RMB 6 billion in Chongqing.
A12 藝術空間
Co-CEO
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
